For example, BLM and LRP1B are not significantly associated with the prognosis of ccRCC, but in the 1123 panel, we observed that the frequency exceeded 10%, so the 79 gene panel may be more suitable for profiling RCC gene mutation. This evidence concerns the gene BLM and renal cell adenocarcinoma.